






































Randomized, Placebo Controlled Trial of Experimental
Hookworm Infection for Improving Gluten Tolerance in
Celiac Disease
JohnCroese,MD1,2,GregoryC.Miller, FRCPA3, LouiseMarquart,PhD4,StaceyLlewellyn,BSc4,RohitGupta, FRACP2, LukeBecker,BAppSci2
, Andrew D. Clouston, PhD3, Christine Welch, FRACP5, Julia Sidorenko, PhD6, Leanne Wallace, BSc6, Peter M. Visscher, PhD6,
Matthew L. Remedios, FRACP7, James S. McCarthy, MD4, Peter O’Rourke, PhD4, Graham Radford-Smith, PhD4, Alex Loukas, PhD2,
Mark Norrie, PhD8, John W. Masson, FRACP5, Richard B. Gearry, PhD9, Tony Rahman, PhD1,2 and Paul R. Giacomin, PhD2
INTRODUCTION: Celiac disease is an autoimmune disorder where intestinal immunopathology arises after gluten
consumption. Previous studies suggested that hookworm infection restores gluten tolerance; however,
these studies were small (n 5 12) and not placebo controlled.
METHODS: We undertook a randomized, placebo-controlled trial of hookworm infection in 54 people with celiac
disease. The 94-week study involved treatment with either 20 or 40 Necator americanus third-stage
larvae (L3-20 or L3-40) or placebo, followed by escalating gluten consumption (50mg/d for 12 weeks,
1 g intermittent twice weekly for 12 weeks, 2 g/d sustained for 6 weeks, liberal diet for 1 year).
RESULTS: Successful study completion rates at week 42 (primary outcome) were similar in each group (placebo:
57%,L3-20:37%,andL3-40:44%;P50.61), however gluten-relatedadverseeventswere significantly
reduced in hookworm-treated participants: Median (range) adverse events/participant were as follows:
placebo, 4 (1–9); L3-20, 1 (0–9); and L3-40, 0 (0–3) (P5 0.019). Duodenal villous height:crypt depth
deteriorated similarly compared with their enrolment values in each group (mean change [95%
confidence interval]: placebo,20.6 [21.3 to 0.2]; L3-20,20.5 [20.8 to 0.2]; and L3-40,21.1 [21.8
to 0.4]; P5 0.12). A retrospective analysis revealed that 9 of the 40 L3-treated participants failed to
establish hookworm infections. Although week 42 completion rates were similar in hookworm-positive vs
hookworm-negative participants (48% vs 44%, P5 0.43), quality of life symptom scores were lower in
hookworm-positive participants after intermittent gluten challenge (mean [95% confidence interval]:
38.9 [33.9–44] vs 45.9 [39.2–52.6]).
DISCUSSION: Hookworm infection does not restore tolerance to sustainedmoderate consumption of gluten (2 g/d) but
was associated with improved symptom scores after intermittent consumption of lower, intermittent
gluten doses.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A450; http://links.lww.com/CTG/A451
Clinical and Translational Gastroenterology 2020;11:e00274. https://doi.org/10.14309/ctg.0000000000000274
INTRODUCTION
Celiac disease (CeD) is an acquired autoimmune enteropathy
with a complex pathogenesis (1). Dietary gluten is normally
catalyzed to form glutamine-rich peptides that are deamidated by
tissue transglutaminase (tTG). Genetically susceptible people
express HLA-DQ2 or HLA-DQ8 proteins on antigen-presenting
cells, which can bind deamidated gluten epitopes and result in the
induction of proinflammatory T lymphocytes that populate the
small intestine and induce epithelial cell apoptosis, chronic in-
flammation, and villous atrophy (2). Autoantibodies induced
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against tTG correlate with mucosal inflammation (3,4). The
condition is becoming increasingly diagnosed and is estimated to
affect 2% of many ethnically diverse populations (5,6). Strict
compliance with a gluten-free diet is the only effective treatment,
but the diet is inconvenient and expensive, and inadvertent gluten
exposures are common (7), which can cause debilitating symp-
toms such as vomiting, diarrhea, and diminished well-being (8).
Helminth parasites are recognized as global pathogens that
have coevolved with humans (9). Necator americanus, once
ubiquitous, has exquisitely adapted to its human host, such that
most infections in well-nourished populations are subclinical
(10). A survival strategy used by helminths is to induce regulatory
immune responses, immunomodulation that has a collateral ef-
fect on concomitant inflammatory diseases of the host (11,12).
Previously, we undertook a N. americanus vs placebo-controlled
trial in people with CeD (13), where participants were abruptly
challenged with gluten (16 g of gluten daily); however hookworm
infection was not associated with improved outcomes after this
abrupt challenge. Subsequent observation of the immunomod-
ulatory impact of hookworm infection on gluten tolerance
(14–16) was the impetus for a follow-up study to address whether
hookworm treatment, when combined with gluten de-
sensitization immunotherapy akin to that trialed for CeD (17)
and food allergies (18), promotes a beneficial regulatory immune
response in the intestine and restores gluten tolerance (19). In
that open-label study, 12 participants were primed with daily
consumption of trace gluten (50 mg daily), after which 10 of the
12 comfortably tolerated 12 weeks of intermittent gluten bolus
challenges (1 g/d twice weekly). Duodenal histologic scores at
completion were similar to baseline assessments; tTG values
improved, as did their quality of life (QoL) scores, suggesting that
gluten microchallenge in the presence of a hookworm infection
might help restore gluten tolerance.
This study expands on the open-label study, by comparing
gluten microchallenge alone vs hookworm inoculation plus
microchallenge, for restoring tolerance to escalating gluten con-
sumption. The primary outcomewas the relative rates of critically
monitored safe completion after 30 weeks of gluten challenges
(concluding with 2 g/d for 6 weeks). Detailed safety evaluations
were also conducted at interim assessment visits to identify tol-
erance to 50 mg of gluten daily and twice weekly 1-g challenge,
which mimics exaggerated real-life exposures to gluten boluses.
METHODS
Study sites and regulatory approvals
BetweenMarch 2017 andOctober 2019, we conducted a phase 1b
randomized, double-blinded, placebo-controlled trial of experi-
mental hookworm infection in otherwise healthy people with
documented CeD. The study included 4 clinical sites: 3 within
Queensland, Australia (The Prince Charles Hospital, Brisbane;
Logan Hospital, Logan; and Townsville University Hospital,
Townsville) and 1 in New Zealand (Christchurch Hospital, New
Zealand). The study designatedHREC/16/QPCH/206 (Australia)
andHDEC/16/CEN/117 (NewZealand) was approved onAugust
31, 2016, and October 25, 2016, respectively, by the Human Re-
search Ethics Committee at the Prince Charles Hospital,
Chermside Queensland, Australia, and the Central Health and
Disability Ethics Committee, Wellington, New Zealand. The trial
was registered with ClinicalTrials.gov, Protocol Record
NCT02754609 on April 28, 2016.
Participants
Entry criteria included otherwise healthy men and women aged
18–80 years with verified documentation of CeD including pre-
treatment Marsh 3 histology score and elevated serum immu-
noglobulin A (IgA)-anti-tTG result. Exclusion criteria in brief
included pregnancy, a history of substance abuse or regular
medications likely to affect immune function, and/or poorly
controlled diseases that might interfere with trial outcomes.
Applicants were initially screened for eligibility through in-
terview, a review of their documentation relating to CeD, and
confirmation of current and uninterrupted adherence to a gluten-
free diet for .6 months. Applicants were then assessed for
compliance with inclusion/exclusion criteria, and confirmation
of current CeD inactivity determined by serology (IgA-anti-tTG
,7U/mL), histology (Marsh 0 or 1 with a Vh:Cd ratio$2), and a
CeD symptom index (CSI) ,35.
Randomization and administration of treatments
Sixty participants were to be included in the trial, randomly allo-
cated on a 1:4:1 ratio according to a computer-generated sequence
to 1 of the 3 study arms: placebo (n5 10), 203Necator americanus
third-stage larvae (L3-20; n5 40) or 403 larvae (L3-40; n5 10),
stratified evenly by baseline Vh:Cd ratio (over or below Vh:Cd of
3.0). Participants and investigators were blinded to the treatment,
other than the assignedproducer of the inocula (coauthor L.B.) and
a medical monitor (coauthor G.R.S.). The inocula were prepared
freshly at James CookUniversity in Cairns, Australia, as previously
described (19) (see Supplementary Methods, Supplementary
Digital Content 2, http://links.lww.com/CTG/A451). Two doses of
inocula were administered 8 weeks apart, with L3-20 and L3-40
participants receiving 103or 203L3on each occasion (Figure 1a).
Hookworm infection status was monitored at weeks 12 and 24
using quantitative PCR on fecal samples (20).
Gluten challenges
Gluten challenge commenced approximately 4 weeks after the
final treatment. The study was conducted with 5 phases designed
to test tolerance to different levels of gluten consumption
(Figure 1a). Beginning with a 12-week treatment phase while
consuming a gluten-free diet (phase i), there followed 4 sequential
challenge phases where gluten was provided as wheat pasta
(Barilla Spaghettini No. 3; 12% protein, estimated 6% dry weight
of gluten). Gluten challenges were as follows: phase ii—12 weeks
priming microchallenge with 10 mg daily for 2 weeks then 50 mg
daily for 10 weeks (1.5 spaghetti straws); phase iii—12 weeks
provocation with 50 mg of gluten daily and 1 g twice weekly
(25–30 spaghetti straws); and phase iv—6 weeks sustained chal-
lenge with approximately 2 g of gluten daily (50–60 spaghetti
straws or, in some instances, 1 slice of bread with comparable
gluten content). After completion of the primary 42-week study
andunblinding, participants in the L3-20 andL3-40 armswithout
CeD symptoms were offered an optional 12-month extension to
the study that involved consumption of an unrestricted gluten-
containing diet exceeding 10 g/d (phase v). All participants dis-
played consistent adherence to gluten-free diet before and during
the trial (other than trial-prescribed gluten), which was docu-
mented weekly on a gluten score card.
Outcome measures
At each designated visit, safety assessments were conducted to
identify adverse events (AEs) and serious AEs. The site principle









Figure1.Study time line, interventions, andCONSORT flow chart. (a) After screening andbaseline analyses, participantswith CeDwere allocated to receive
either placebo (chilli pepper solution) or hookworm larvae (L3-20 or L3-40) delivered over 2 occasions, at week 0 andweek 8 (phase i). L3 denotesNecator
americanus stage 3. At week 12, subjects received a 12-week gluten priming challenge (phase ii: 10–50 mg/d for 12 weeks), followed by a gluten
provocation challenge (phase iii: 50 mg/d 11 g twice weekly for 12 weeks) and sustained gluten challenge (phase iv: 2 g/d for 6 weeks). At week 42,
following evaluation of patient symptoms, the study became unblinded and participants in active L3-treated cohorts were given the option of undertaking a
monitored “liberal diet” of at least 10 g of gluten/day, with freedom of food choice for 12 months (phase v). Participants underwent regular clinic visits as
denoted by the black triangles, where various biological samples and survey assessments were taken for analysis of safety and CeD pathology. #Denotes
endoscopy performed at week 12 instead of week 36 in the L3-40 cohort. (b) CONSORTchart showing flow of patients through the clinical trial. AE, adverse
event; CeD, celiac disease; CSI, CeD symptom index survey; QoL, CeD quality of life survey; SAE, serious AE.
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investigator and the medical monitor were immediately notified
of an adverse result. Each participant was required to complete a
CSI weekly until week 42 and monthly thereafter. Blood, fecal,
and duodenal biopsy samples were taken at weeks 12, 24, 36, and
42. The biopsy schedule was designed to limit interventions to a
maximum of 2 per individual after baseline, with L3-40 partici-
pants scheduled for biopsy at weeks 12 and 42, and the L3-20 and
placebo cohorts at weeks 36 and 42. The alternative L3-40 en-
doscopy schedule was to evaluate hookworm infection in iso-
lation on intestinal biology. The primary outcome assessed at
week 42 was the safety of sequential gluten challenges (phases
ii–iv), assessed by adverse events, symptoms, anti-tTG serology,
and qualitative and quantitative histological parameters, defined
as a binary variable (pass or fail). Specific criteria were as follows:
Pass if week 42 visit successfully completedwith tTG,10 andVh:
Cd$2.0 (Marsh 0 or 1);
Fail if dropout occurs before week 42, or tTG$10, or Vh:Cd,2.0
(Marsh 3).
Secondary endpoints to evaluate tolerance to lower levels of gluten
consumption included serological, histological (as available), and
symptom scores completed after phases ii and iii (see Supple-
mentary Methods, Supplementary Digital Content 2, http://links.
lww.com/CTG/A451). During the liberal diet, each participant was
monitored monthly by tTG and CSI.
Statistical analyses
Associations between treatment groups for the primary outcome
and categorical secondary measures were examined using x2 tests
of independence or the Fisher exact test, where .20% of the
expected values were,5. Associations for the change in continu-
ous secondary measures from baseline to week 42 between groups
were examined using a 1-way ANOVA or Kruskal-Wallis test,
where the assumptions of data normality were not met. Where
differences between treatment groups were not important, evi-
dence of an overall change for measures were assessed using a 1
sample t test orWilcoxon signed-rank test, where the assumptions
of data normality were notmet. Categorical clinical measures were
summarized by frequency and percentage and continuous mea-
sures were summarized bymean and 95% confidence interval (CI)
or median and interquartile range for nonnormally distributed
data. Where appropriate, exploratory analysis of the change from
baseline to week 42 of secondary outcomes between participants in
alternative 2 treatment groups was assessed using a 2-sample t test.
The Kaplan-Meier analysis was used to estimate the cumulative
probability of participant dropouts from baseline to the week 42,
with associations between treatment groups assessed using the log-
rank test statistic. Statistical analyses were performed in Stata
version 15 (StataCorp, College Station, TX).
RESULTS
Study population
Seventy-seven applicants with CeD whose diagnosis met validation
criteria were screened for eligibility based on protocol inclusion/
exclusion criteria (see Supplementary Methods, Supplementary Dig-
ital Content 2, http://links.lww.com/CTG/A451). Twenty-three par-
ticipantswere excluded: 13with tTG$7U/mLand 10with duodenal
histopathology (Marsh 2–3, or Vh:Cd , 2) (Figure 1b). Fifty-four
participants (90% of the recruitment target) were randomized and
constituted the intention-to-treat population (see Supplementary
Table 1, Supplementary Digital Content 2, http://links.lww.com/
CTG/A451). Seven participants were allocated to receive placebo
treatment, 38 to receive L3-20 treatment, and 9 to receive L3-40
(Figure 1b). HLA imputation analysis (see Supplementary Methods
and Supplementary Table 2, SupplementaryDigital Content 2, http://
links.lww.com/CTG/A451) confirmed the presence of the DQ2/DQ8
CeDrisk alleles for all studyparticipantswho consented to genotyping
analysis (mean posterior probability of 0.97 for bothHLA-DQA1 and
HLA-DQB1; see Supplementary Table 3, Supplementary Digital
Content 2, http://links.lww.com/CTG/A451).
AEs and serious AEs
Themost commonAEs recorded in thefirst 12weeks (hookworm
priming—phase i) were abdominal pain, diarrhea, fatigue, nau-
sea, appetite loss, flatulence, or bloating (Table 1). During the
gluten challenge phases (weeks 12–42), the most common AEs
were diarrhea, abdominal pain, nausea, fatigue, headache, vom-
iting, bloating, andmuscle aches. Comparedwith placebo-treated
participants, hookworm-treated participants exhibited signifi-
cantly fewer AEs during the gluten challenge period (Table 1).
Similarly, the percentage of participants in the hookworm treat-
ment groups who experienced at least 1 AE during the gluten
challenge phases was reduced, comparedwith that in the placebo-
treated participants (Table 1). No participant developed iron
Table 1. Summary of median (range) number of adverse events (AEs) and proportions of participants experiencing at least 1 AE, classified
by AE type
Number AEs per participant Proportion with ‡1 AE
Placebo (n5 7) L3-20 (n 5 38) L3-40 (n 5 9) P Placebo (n5 7) L3-20 (n 5 38) L3-40 (n 5 9) P
Any AE 5 (1–14) 3 (0–16) 2 (0–8) 0.35 7 (100%) 34 (89%) 8 (89%) 0.66
Hookworm (week 0–12) NA 1 (0–4) 1 (0–4) 0.86 NA 20 (53%) 5 (56%) 0.87
Gluten (week 12–42) 4 (1–9) 1 (0–9)a 0 (0–3)b 0.019 7 (100%) 21 (60%)a 3 (38%)b 0.038
Unrelated (any week) 1 (0–5) 1 (0–5) 1 (0–6) 0.77 4 (57%) 25 (66%) 6 (67%) 0.90
Serious AE 0 (0–0) 0 (0–1) 0 (0–0) 0 (0%) 1 (3%) 0 (0%)













deficiency or anemia (see Supplementary Figure 1A and B, Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A450),
the major clinical effect of hookworm infection.
Primary outcome measure: successful study completion at
week 42
Of the 54 participants included in the intention-to-treat analysis, 7
participants were withdrawn from the study because reasons not
attributed to prescribed gluten. Five of the 7were removed before the
introduction of the gluten challenge: 2 participants in the L3-20
cohort with suspected hookworm-related enteric symptoms from 6
to 8 weeks (Figure 1b), both of whom received anthelmintic treat-
ment that resulted in a prompt resolution; 2 participants in theL3-20
cohort withdrew at week 12, one without explanation and one be-
cause of a recurrence of Graves thyrotoxicosis; and one L3-40 par-
ticipant with a pretrial histology gradedMarsh 0 was excluded after
the week 12 biopsy established Marsh 3 pathology (Figure 2). The
remaining 2 participants were withdrawn due to unrelated condi-
tions: onebecauseof a recurrenceof adepressive illness; andonewith
an unrelated gynecological event (serious AE) (Figure 1b).
Twelve participants displayed symptomatic gluten toxicity
(placebo: n 5 2, L3-20: n 5 5) or developed Marsh 3 histology
Figure 2.Heatmap displaying safety assessment outcomes and completion of study phases. Color-coded heatmap displayingMarsh score, IgA-tTG safety
assessment results and dropouts in the intention-to-treat (a) placebo, (b) L3-20, and (c) L3-40 cohorts at baseline and at designated visits after escalating
gluten challenge. Marsh 3 represents failed histology; t denotes failed tTG assessment. Each row represents an individual participant. tTG, tissue
transglutaminase.
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(L3-20: n 5 4, L3-40: n 5 1, Figure 2) before the week 42 as-
sessment and, thus, failed tomeet the primary endpoint. Fourteen
participants failed the week 42 assessment: 4 (placebo: n5 1, L3-
20: n5 3) due to raised tTG alone; 6 (L3-20: n5 4, L3-40: n5 2)
due to failed histology alone; and 4 (L3-20: n5 3, L3-40: n5 1)
due to failed tTG and histological results (Figure 2).
Four of 7 placebo-treated participants successfully completed
the study, maintaining Marsh 0 or 1 grade pathology and normal
tTG (Figure 2a). Similarly, 14 of the 38 in the L3-20 group and 4 of
the 9 in the L3-40 group successfully completed theweek 42 safety
assessments (Figure 2b,c). Primary analysis of the intention-to-
treat study population at week 42 revealed that successful com-
pletion rates were similar between the 3 study groups (Table 2; P
5 0.61). Rates of completion of the interim study phases did not
differ between the 3 treatment groups (Table 2).
Secondary outcome measures: histology, IgA anti-tTG, and
symptom scores
For analysis of secondary outcomes, we excluded results from the
7 participants who were removed from the study because of
reasons not attributed to prescribed gluten or hookworm. Anal-
ysis of changes in histological parameters Vh:Cd and intra-
epithelial T (IET) cell counts in the combined study cohort identified
significant deterioration in both parameters at week 42 compared
with those at baseline (P , 0.001, Table 3). Relative changes in
Vh:Cd (P5 0.12) and IET% (P5 0.21) were similar between the 3
study groups (Figure 3a,b and see Supplementary Table 4, Sup-
plementary Digital Content 2, http://links.lww.com/CTG/A451).
IgA anti-tTG titers remained stable across the combined study
group until week 36 but significantly rose after the sustained
gluten challenge at week 42 (P , 0.001, see Supplementary Ta-
ble 4, Supplementary Digital Content 2, http://links.lww.com/
CTG/A451). Relative changes in anti-tTG titers among the 3
groups were similar (P 5 0.49, Figure 3c and see Supplementary
Table 4, Supplementary Digital Content 2, http://links.lww.com/
CTG/A451). CSI scores in the combined study cohort were similar
atweek 42comparedwith those at baseline (mean changeCSI [95%
CI]:21.0 [22.3 to 0.3], P5 0.14), with no differences between the
3 study groups (P 5 0.14, see Supplementary Table 4, Supple-
mentaryDigital Content 2, http://links.lww.com/CTG/A451).QoL
scoreswere significantly improved in the combined study cohort at
week 42 compared with those at baseline (mean change QoL [95%
CI]: 27.2 [211.0 to 23.4], P , 0.001); however, there were no
differences in change in QoL score among the 3 study groups (P5
0.12; see SupplementaryTable 4, SupplementaryDigital Content 2,
http://links.lww.com/CTG/A451).
Evaluation of cellular immune response and
hookworm establishment
Hookworm infection is associated with induction of blood eo-
sinophilia, peaking between weeks 6 and 12 (10,21,22). Eosino-
phil counts remained stable in the placebo cohort throughout but
were increased in the L3-20 and L3-40 cohorts at week 12, before
declining to near baseline levels by week 42 (Figure 4a). However,
eosinophilia was not universal, with only 28 of the 40 individuals
in the L3-20 and L3-40 groups reaching the upper limit of normal
for clinical eosinophilia (0.6 3 109 cells/mL; Figure 4b), sug-
gesting suboptimal establishment of hookworm infection. Anal-
ysis of fecal samples taken at weeks 12 and 24 revealed that 9 of 40
L3-20 or L3-40 participants did not have evidence of N. ameri-
canus infection (negative for hookworm by PCR; negative for
eosinophilia; Figure 4c). Using a composite definition of hook-
worm infection (hookworm PCR1 and/or elevated eosinophil
count), 31 of 40 participants were deemed to have established
Table 2. Number and proportion of participants successfully completing each study phase
Completion rates of each study stage
Placebo (n5 7), n (%) L3-20 (n5 38), n (%) L3-40 (n5 9), n (%)
Phase i: hookworm priming (week 12) 7 (100) 34 (89) 8 (89)
Phase ii: gluten priming (week 24) 7 (100) 30 (79) 8 (89)
Phase iii: gluten provocation (week 36) 5 (71) 23 (61) 7 (78)
Phase iv: sustained gluten (week 42) 4 (57) 14 (37) 4 (44)
After the week 42 clinic visit, 16 participants in the L3-20 or L3-40 groups elected to commence the open-label trial extension involving consumption of a liberal diet for 1
year. Four participants survived all safety checks and attended aweek 94 clinic assessment, whereas 12 participants failed within the first 20 weeks due to sharply elevated
monthly CSI or tTG values. Grading of exit biopsies at study completion in 4 participants who reachedweek94 revealed that 2 exhibitedMarsh 3 gradeCeD accompaniedby
normal CSI and anti-tTG titers, whereas the other 2 showed no signs of CeD pathology.
CeD, celiac disease; CSI, CeD symptom index; tTG, tissue transglutaminase.
Table 3. Histology and autoantibody responses in study population combined
Vh:Cd ratio, mean (95% CI) IET%, median (IQR) tTG (U/mL), median (IQR)
Baseline (N 5 47) 2.7 (2.6–2.9) 19 (15–27) 1 (1–3)
Week 36 (N 5 40) 2.3 (2.1–2.5)a 34 (23–51)a 2 (1–3)
Week 42 (N 5 35) 2.1 (1.9–2.3) 42 (25–65) 3 (1–5)
CI, confidence interval; IET, intraepithelial T cell; IQR, interquartile range; tTG, tissue transglutaminase. Vh:Cd, Villous height: Crypt depth
an 5 34.









Figure 3. Histology and serum autoantibody (anti-tTG) responses. (a) Duodenal villous height:crypt depth ratio (Vh:Cd, mean 6 95% CI) and (b)
intraepithelial CD31 T cell (IET cell) frequency (median 6 IQR) in each individual’s duodenal biopsy specimen at baseline and each study visit after
intervention and escalating gluten challenge. (c) Serum IgA-tTG titers (median 6 IQR) at baseline and each study visit. Dot points represent each
individual’s value and grayed area indicates the normal ranges for each parameter. CI, confidence interval; Hw, hookworm; IgA, immunoglobulin A; IQR,
interquartile range; n/a, not applicable; tTG, tissue transglutaminase.
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successful hookworm infections (Figure 4c). Of note, 6 of the 9
participants without evidence of infection were from the New
Zealand-based clinical site.
Analysis of outcomes in hookworm-positive vs hookworm
negative participants.
As an exploratory analysis, we investigated the effect of reclassi-
fying the 9 participants in the active arms who lacked evidence of
hookworm infection into a “hookworm-negative” group, along
with the 7 placebo participants. Although successful completion
rates to week 42 were comparable in the 31 hookworm-positive
and 16 hookworm-negative participants (48% vs 44%, re-
spectively, P5 0.43), rates of progression through interim phases
tended to be greater in the hookworm-positive group (Figure 5a).
The Vh:Cd values were comparable between hookworm-positive
and -negative participants (Figure 5b). Changes in baseline to
week 42 CSI scores were also similar (mean change CSI [95% CI]:
hookworm-negative: 1.2 [24.8 to 2.4], hookworm-positive:20.9
[22.3 to 0.5], P 5 0.84, Figure 5c). Both groups also exhibited
comparable changes in baseline with week 42 QoL values (mean
change QoL [95% CI]: hookworm negative:26.9 [216.7 to 2.9],
hookworm positive: 27.4 [211.5 to 3.2], P 5 0.91, Figure 5d).
However, assessment of QoL scores at an interim time point
(week 36) suggested that hookworm-positive participants dis-
played lowered QoL scores compared with their baseline value
and with hookworm-negative participants (mean QoL [95% CI]
baseline–week 36: hookworm positive: 46.5 [41.3–51.8] to 38.9
[33.9–44]; hookworm negative: 47.1 [39.6–54.5] to 45.9
[39.2–52.6], Figure 5d).
DISCUSSION
We postulated that treating CeD participants with hookworm N.
americanus larvae would be well tolerated and that the immuno-
modulation induced by the wormsmight have a collateral effect of
improving gluten intolerance in CeD, compared with placebo
treatment. Although the results from this study mirror those pre-
viously reported by us (19), the ambitious primary outcome to
establish tolerance to sustained gluten consumption (2 g daily for 6
weeks) was not achieved; thus, it is evident that hookworm in-
fection does not obviate the need for a gluten-free diet.
Our hypothesis was that gradual reintroduction of gluten alone
(in placebo-treated participants) would provide limited protection
against sustained gluten challenge, which might be improved by
hookworm treatment. Indeed, escalating gluten challenge did result
in gradual deterioration of the duodenal mucosa, but this was irre-
spective of the treatment group. Although it was somewhat sur-
prising that over half of the placebo-treated participants successfully
completed week 42 with tTG and duodenal histology results within
normal ranges, this was based on a very small sample size. Gradual
gluten desensitization strategies through oral exposure or parenteral
vaccination have already been trialed for CeD with limited efficacy
(Nexvax2, NCT03644069) (23); hence, it remains unclear whether
maintaining low-level exposure alone is beneficial for promoting
gluten tolerance. It is possible that targeting mucosal antigen-
Figure 4. Evaluation of establishment of hookworm infections. (a) Peripheral blood eosinophil counts at baseline, after treatment with placebo or hookworm
L3, and after escalating gluten challenges. Each individual data point is shown along with mean 6 95% confidence interval. Grayed area indicates the
normal range. (b) Peak eosinophil counts in each participant from the L3-30 or L3-40 cohorts were ranked from lowest to highest and correlatedwith the (c)
detection of hookworm eggs in feces by quantitative polymerase chain reaction (patency). F denotes participants who demonstrated both a lack of clinical
eosinophilia (,0.63 109/L) and an absence of a patent hookworm infection (total of 9 participants were deemed to be “hookworm treatment failures”).









presenting cells might lead to more positive outcomes, particularly
for vaccination strategies. In this study, we used hookworms as an
alternative strategy to target the mucosal immune system and
reported that hookworm-infected participants did seem more re-
silient than hookworm-negative participants about gluten-related
adverse events and QoL indices, particularly during the gluten
provocation phase (up to week 36). This positive result is consistent
with observations in both our previous trials and might relate to a
sense of improved general well-being after hookworms have estab-
lished in the gut (13,19). This hypothesis is supported by the decision
Figure 5. Analysis of outcomes in hookworm-positive vs hookworm-negative participants. (a) Kaplan-Meier analysis of rates of trial continuation (%) during
the various phases of the trial in the 31 hookworm-positive participants vs the 16 hookworm-negative participants, displayed as mean survival 6SEM.
Survival required stable (Marsh 0 or I) intestinal pathology, subclinical immunoglobulin A-tissue transglutaminase titer (,10 units) and asymptomatic
tolerance to the gluten challenge. (b) Duodenal villous height:crypt depth ratio (Vh:Cd) in hookworm-negative vs hookworm-positive participants. Each
individual data point is shown alongwithmean6 95%confidence interval. Grayed area indicates the normal ranges. (c) Mean CeD symptom index (CSI) in
each group, averaged for each 3-week period. (d) Mean CeD quality of life (QoL) score695% CI determined at each clinic visit. For both CSI and QoL, a
lower value indicates lessened CeD-related symptoms. CeD, celiac disease.
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of virtually every participant to retain the infection when exiting this
and previous trials.
This study incorporated multiple distinct challenge phases
designed to replicate clinical scenarios. First, a dose-ranging run in
was undertaken to test the safety and tolerability of inoculation
with 40L3 comparedwith 20L3. Consistent with previousfindings
(19), hookworm infection was mostly well-tolerated, other than
two L3-20 participants who withdrew due to transient symptom-
atic enteritis, a characteristic of primarybut not chronichookworm
disease (21,22). Both promptly responded to anthelmintic therapy.
Unexpectedly, establishment of hookworm infection failed in ap-
proximately one-quarter of participants. In our previous studies
(13,19) and those of others (10,24), a single study site was mostly
involved, anduniformbatching of L3 inoculawas undertaken. This
study involved 4 clinical sites in 2 countries and 14different batches
of L3. Although the production is scrupulously supervised to
maintain consistency, the process lacks Good Manufacturing
Practice certification. Most failed inoculations occurred at the
overseas site most distant from the production center, suggesting
that extended transit time and handling might have compromised
larval viability. Understanding of the optimal production meth-
odology, storage, and transport conditions tomaintain the integrity
of infective hookworm larvae will be necessary in future studies.
Promptedby thehygienehypothesis, studies inmurinemodels of
inflammatory bowel disease supported a role for live helminths and
helminth-secreted products to mitigate disease activity (25). The
initial clinical trials in patients with active inflammatory bowel dis-
ease infected with porcine whipworm ova were reported positively
(26,27), as were a small study in patients with Crohn’s disease
infected with N. americanus (28) and a case study with Trichuris
trichiura (29). Subsequent trials covering a spectrum of allergic and
inflammatory diseases, including a recent trial in multiple sclerosis
(30), have universally failed to show a statistically significant benefit
(31). Although these negative results have resulted in the loss of
professional support for “live helminth” therapy, it still garners en-
thusiasm as an alternative medical therapy (32). The lack of efficacy
seen in some studies might relate to the application of helminths
during active inflammatory disease, where helminthsmight bemore
suited as a preventative therapy given before disease induction.
This study included design and conduct limitations, including
the small sample size (particularly in the placebo cohort) and the
inconsistencies of outcome scores to properly reflect disease activity.
Through necessity, the cohorts were small, consistent with the trial’s
phase 1b status. The small placebo cohort offered limited chance for
delivering a statistically significant difference between the intention-
to-treat cohorts. Relating to outcome scoring, no single outcome
predictably quantified CeD activity. We monitored CeD-specific
symptoms in response to gluten consumption (CSI), tTG, and
quantitative and qualitative histologic parameters. Of concern, there
existed poor uniformity between these parameters.Most concerning
was that several participants who remained asymptomatic and had
normal tTG had acquired Marsh 3 active CeD status. Longitudinal
anti-tTG values were remarkably consistent and frequently failed to
correlate with histologic evidence of disease reactivation. Quantita-
tive histological scoring also proved an inconsistent predictor of
disease activity. Several participants incongruously returned an
improved Vh:Cd after gluten challenge, and in 1 case after in-
oculationwithL3-40, theweek 12Vh:Cd score andMarsh grade had
deteriorated dramatically in the absence of known gluten exposure.
In conclusion, neither trace gluten nor hookworm treatment
universally protects against relaxation of a gluten-free diet. Daily
consumption of 50 mg of gluten induced limited meaningful ad-
verse events in most participants (.90% study progression beyond
week 24); however, sustained gluten challenges of 2 g/d resulted in
deterioration of the duodenal mucosa by week 42, irrespective of
hookworm treatment. The improvement in symptom scores and
wellbeing after hookworm infection during lower doses of gluten
challenge seems real and might have clinical relevance. To un-
derstand these observations, further clinical trials and detailed
mechanistic evaluations of the biological responses that are asso-
ciatedwithhookworm infection andgluten ingestion arewarranted.
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Study Highlights
WHAT IS KNOWN
3 Hookworms suppress inflammation within the gut, the
same tissue that develops immunopathology in celiac
disease.
3 A small, open-label trial showed hookworm infection enabled
gradual reintroduction of gluten to patients with celiac
disease.
WHAT IS NEW HERE
3 This larger, placebo-controlled trial shows that daily low-dose
gluten (,50 mg/d) induced limited adverse events,
irrespective of hookworm treatment.
3 Hookworm infection did not improve tolerance to moderate
gluten challenge (2 g/d).
3 Hookworm-treated participants had fewer adverse symptoms
and improved quality of life scores during lower gluten
challenges.
TRANSLATIONAL IMPACT
3 Hookworm treatment does not cure celiac disease, but the
observed improvements in symptoms may have clinical
relevance for the wellbeing of people with celiac disease.
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